Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease [1] [2].
In Vivo, Rezuforimod (AG-80308) is a dry eye inhibitor administered via topical eye drops. When administered twice daily (BID) for 3 consecutive months, it exhibits significant anti-inflammatory and symptom-improving efficacy with favorable overall safety, as evidenced by the following:\n It significantly reduces corneal and conjunctival staining scores, with the maximum reductions in corneal staining from baseline observed on Day 43 and Day 84, while also improving the Ocular Surface Disease Index (OSDI) score[1].
References:
[1]. Ridder III W H, et al. New drugs for the treatment of dry eye disease[J]. Clinical Optometry, 2015: 91-102.
[2]. Cheetham J K, et al. AG-80308, a novel first-in-class ophthalmic solution for the treatment of dry eye disease[J]. Investigative Ophthalmology & Visual Science, 2024, 65(7): 2984-2984.
In Vivo, Rezuforimod (AG-80308) is a dry eye inhibitor administered via topical eye drops. When administered twice daily (BID) for 3 consecutive months, it exhibits significant anti-inflammatory and symptom-improving efficacy with favorable overall safety, as evidenced by the following:\n It significantly reduces corneal and conjunctival staining scores, with the maximum reductions in corneal staining from baseline observed on Day 43 and Day 84, while also improving the Ocular Surface Disease Index (OSDI) score[1].
References:
[1]. Ridder III W H, et al. New drugs for the treatment of dry eye disease[J]. Clinical Optometry, 2015: 91-102.
[2]. Cheetham J K, et al. AG-80308, a novel first-in-class ophthalmic solution for the treatment of dry eye disease[J]. Investigative Ophthalmology & Visual Science, 2024, 65(7): 2984-2984.